Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-03-11 7:56 pm Unchanged | 2024-03-07 | 13D | PEPGEN INC PEPG | RA CAPITAL MANAGEMENT L.P. | 10,695,135 33.100% | 0 (Unchanged) | Filing History |
| 2024-03-06 6:54 pm Purchase | 2024-03-04 | 13D | JANUX THERAPEUTICS INC JANX | RA CAPITAL MANAGEMENT L.P. | 10,593,395 19.990% | 1,922,751 (+22.18%) | Filing History |
| 2024-03-06 6:50 pm Purchase | 2024-03-04 | 13D | 89BIO INC ETNB | RA CAPITAL MANAGEMENT L.P. | 14,254,298 14.800% | 1,378,443 (+10.71%) | Filing History |
| 2024-02-27 4:19 pm Sale | 2024-02-23 | 13D | CONNECT BIOPHARMA HLDGS LTD CNTB | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -3,062,871 (Position Closed) | Filing History |
| 2024-02-26 4:17 pm Purchase | 2024-02-16 | 13G | LARIMAR THERAPEUTICS INC LRMR | RA CAPITAL MANAGEMENT L.P. | 6,045,351 9.500% | 6,045,351 (New Position) | Filing History |
| 2024-02-22 7:07 pm Unchanged | 2023-12-31 | 13G | CYTEK BIOSCIENCES INC CTKB | RA CAPITAL MANAGEMENT L.P. | 6,809,404 5.200% | 0 (Unchanged) | Filing History |
| 2024-02-21 4:17 pm Sale | 2024-02-19 | 13D | ICOSAVAX INC ICVX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -5,985,843 (Position Closed) | Filing History |
| 2024-02-14 9:08 pm Sale | 2023-12-31 | 13G | EYEPOINT INC EYPT | RA CAPITAL MANAGEMENT L.P. | 3,095,136 6.100% | -313,570 (-9.20%) | Filing History |
| 2024-02-14 6:41 pm Purchase | 2023-12-31 | 13G | UNICYCIVE THERAPEUTICS INC UNCY | RA CAPITAL MANAGEMENT L.P. | 347,211 9.990% | 142 (+0.04%) | Filing History |
| 2024-02-14 6:35 pm Sale | 2023-12-31 | 13G | ORCHARD THERAPEUTICS PLC ADS N ORTX | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -18,564,300 (Position Closed) | Filing History |
| 2024-02-14 5:17 pm Purchase | 2024-02-12 | 13D | WEREWOLF THERAPEUTICS INC HOWL | RA CAPITAL MANAGEMENT L.P. | 6,179,035 15.200% | 19,981 (+0.32%) | Filing History |
| 2024-02-14 5:04 pm Sale | 2023-12-31 | 13G | Tourmaline Bio, Inc. TRML | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -233,318 (Position Closed) | Filing History |
| 2024-02-14 5:03 pm Sale | 2023-12-31 | 13G | NEKTAR THERAPEUTICS NKTR | RA CAPITAL MANAGEMENT L.P. | 0 0.000% | -1,246,667 (Position Closed) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | 4D MOLECULAR THERAPEUTICS INC. FDMT | RA CAPITAL MANAGEMENT L.P. | 4,163,211 9.700% | 1,373,490 (+49.23%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | AN2 THERAPEUTICS INC ANTX | RA CAPITAL MANAGEMENT L.P. | 5,551,295 18.700% | 1,777,778 (+47.11%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | CHIMERIX INC CMRX | RA CAPITAL MANAGEMENT L.P. | 8,800,000 9.900% | 2,298,376 (+35.35%) | Filing History |
| 2024-02-14 5:01 pm Sale | 2023-12-31 | 13G | CUREVAC N V CUREVAC N V IN CON CVAC | RA CAPITAL MANAGEMENT L.P. | 2,744,270 1.200% | -9,501,685 (-77.59%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | IMMUNOGEN INC IMGN | RA CAPITAL MANAGEMENT L.P. | 26,916,027 9.990% | 4,840,869 (+21.93%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | ALPINE IMMUNE SCIENCES INC ALPN | RA CAPITAL MANAGEMENT L.P. | 5,903,234 9.990% | 1,505,866 (+34.24%) | Filing History |
| 2024-02-14 5:01 pm Purchase | 2023-12-31 | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | RA CAPITAL MANAGEMENT L.P. | 10,107,400 17.500% | 140,228 (+1.41%) | Filing History |